InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,716.80
(
0.19%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.21
(
-0.01%
)
Bitcoin
62,880.01
(
-0.04%
)
Post# of 251810
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119628
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 218579

Wednesday, 04/18/2018 5:09:04 PM

Wednesday, April 18, 2018 5:09:04 PM

Post# of 251810

I don’t think the market is pricing nivolumab is indeed inferior to pembrolizumab in 1st line NSCLC and more.

The “and more” is the key. Opdivo has produced excellent data in many different cancer types and settings. If it were truly an inferior drug to Keytruda generally, we would presumably have seen other instances of that by now.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up